NILK-3301 / LamKap Bio, Light Chain Biosci - LARVOL DELTA

"#LamKapBio presented data on #NILK2301 #NILK2401 and #NILK3301 https://t.co/rgAjaee38n" (@1stOncology)

Combination of κλ bispecific antibodies targeting innate (CEAxCD47, NILK-2401) and adaptive immunity (CEAxCD3, NILK-2301 and CEAxCD28, NILK-3301) for next generation immunotherapy of CEA-expressing cancers (AACR 2023) - "NILK-2301 and NILK-2401 are active as single agents. Addition of NILK-2401 or NILK-3301 to NILK-2301 significantly increases activity, already at 10 -100x lower CEAxCD3 doses. GMP drug substance has been produced for NILK-2301 and NILK-2401."

Gastric Cancer • Oncology • Solid Tumor • CD69 • CD8 • CEACAM5 • GZMB • IFNG • IL2RA • SIRPA

Novel CEAxCD3 (NILK-2301) and CEAxCD28 (NILK-3301) κλ bispecific antibodies for next generation immunotherapy of CEA-expressing cancer (ESMO 2022) - "NILK-2301 + NILK-3301 combination treatment significantly increases activity already at low NILK-2301 doses with reduced cytokine release when given sequentially. IND-filing for NILK-2301 is expected in Q4/2022."

IO biomarker • Gastric Cancer • Oncology • CD4 • CD8 • CEACAM5 • IFNG • IL2 • IL2RA • IL6 • TNFA